This study assessed the effectiveness and safety of stereotactic body radiotherapy (SBRT) for treating frail patients with primary renal cell carcinoma (RCC) who cannot undergo surgery or standard treatments.
A total of 23 patients were treated, with promising outcomes including high local control rates (96%) and no severe side effects or treatment-related deaths reported.
The findings suggest that SBRT may serve as a viable alternative treatment option for this patient population, highlighting its potential for good oncological outcomes and tolerable toxicity.